Overview

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a phase I/IIa study to evaluate the safety, tolerability and preliminary efficacy of IAH0968 in patients with HER2-positive advanced solid tumors who have failed standard treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
SUNHO(China)BioPharmaceutical CO., Ltd.
Treatments:
Gemcitabine